Comparative Effectiveness Research/Health Technology Assessment (HTA) Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
Year: 2013
Type: article
Authors: Shannon Cope, Jeroen P. Jansen, Peter Schmid
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2786946485